Hot Pursuit     14-Jun-24
Zydus Life gets tentative USFDA nod for hypertension drugs
The drug major announced that it has received a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets.

Azilsartan and Chlorthalidone is an angiotensin II receptor blocker (ARB) and a thiazide like diuretic combination product indicated for the treatment of high blood pressure (hypertension), to lower blood pressure. The said drug is equivalent to reference listed drug, Edarbyclor tablets.

The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India.

According to IQVIA MAT March 2024 data, Azilsartan Medoxomil and Chlorthalidone tablets had annual sales of $77.9 million in the United States

The group now has 397 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The pharma major reported consolidated net profit of Rs 1,182.3 crore in Q4 FY24 steeply higher than Rs 296.6 crore recorded in Q4 FY23. Revenue from operations jumped 10.44% to Rs 5,533.8 crore during the quarter as compared with Rs 5,010.6 crore posted in corresponding quarter last year.

Shares of Zydus Lifesciences rose 0.85% to trade at Rs 1,099.55 on the BSE.

Previous News
  Zydus receives USFDA tentative approval for Azilsartan Medoxomil and Chlorthalidone Tablets
 ( Corporate News - 14-Jun-24   13:42 )
  Sentynl receives marketing authorisation for NULIBRY® from UK MHRA
 ( Corporate News - 20-Apr-24   17:21 )
  Zydus launches Mirabegron ER Tablets in US market
 ( Corporate News - 22-Apr-24   08:55 )
  Indices trade higher; consumer durable shares rally
 ( Market Commentary - Mid-Session 22-Apr-24   13:37 )
  Zydus Lifesciences to declare Quarterly Result
 ( Corporate News - 31-Jan-24   12:07 )
  Zydus Life edges higher after launching OAB treatment drug Mirabegron in US
 ( Hot Pursuit - 22-Apr-24   09:25 )
  Zydus Lifesciences consolidated net profit rises 26.76% in the December 2023 quarter
 ( Results - Announcements 09-Feb-24   14:29 )
  Zydus Life Q3 PAT climbs 27% YoY to Rs 790 cr; board OKs Rs 600 cr share buyback
 ( Hot Pursuit - 09-Feb-24   14:22 )
  Zydus Life gets USFDA nod for cystic acne drug
 ( Hot Pursuit - 31-Aug-23   13:24 )
  Zydus enters into licensing and supply agreement with MSN Laboaratories
 ( Corporate News - 17-May-24   09:07 )
  Zydus Lifesciences receives USFDA approval for Dapsone Gel 7.5%
 ( Corporate News - 09-May-24   12:36 )
Other Stories
  Bondada Engg board grants nod to 1:5 stock-split
  16-Jul-24   16:52
  Pearl Global spurts after HDFC MF buys stake
  16-Jul-24   16:00
  Bharti Hexacom soars after broker initiates coverage
  16-Jul-24   15:34
  Ujaas Energy hits record high as board OKs 1:4 bonus issue
  16-Jul-24   15:34
  Century Textiles Q1 PAT drops 47% YoY to Rs 28 cr
  16-Jul-24   15:34
  Himadri Specialty spurts after Q1 PAT climbs 42% YoY
  16-Jul-24   15:19
  Jupiter Wagons Ltd leads losers in 'A' group
  16-Jul-24   15:00
  Sheetal Cool Products Ltd leads losers in 'B' group
  16-Jul-24   14:45
  Bajaj Auto gains after Q1 PAT jumps 19% YoY To Rs 1,988 cr
  16-Jul-24   14:41
  Volumes soar at Alembic Pharmaceuticals Ltd counter
  16-Jul-24   14:30
Back Top